The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis

Basit Öğe Kaydı
dc.contributor.authorNathan, Steven D.
dc.contributor.authorBrown, A. Whitney
dc.contributor.authorMogulkoc, Nesrin
dc.contributor.authorSoares, Flavia
dc.contributor.authorCollins, Ashley C.
dc.contributor.authorCheng, Joyce
dc.contributor.authorBarnett, Scott D.
dc.date.accessioned2020-12-01T11:58:41Z
dc.date.available2020-12-01T11:58:41Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: the course of idiopathic pulmonary fibrosis (IPF) is uncertain with variable patterns of disease progression. We sought to evaluate the prognostic utility of the WBC, a routinely performed lab test, in a well-defined cohort of outpatient IPF subjects. Methods: We reviewed IPF patient records from two independent ILD centers (Inova Fairfax in Falls Church, VA, USA and Ege University Hospital in Izmir, Turkey) between 2007 and 2018. Demographics, CBC data, and patient outcomes were obtained. Survival differences were analyzed. Results: There were 436 IPF outpatients in the cohort with a median WBC of 8.9 x 10(9) cells per liter. For pragmatic purposes, patients were categorized into two groups, WBC >= 9 or WBC <9. Patients with WBC <9 had a median transplant-free survival of 50.5 months from the time of the CBC, compared to 32.4 months for those with WBC >= 9 (p < 0.0001). the association between WBC and attenuated survival remained significant after adjusting for GAP stage, steroid use, and antifibmtic use when WBC was analyzed both as a continuous (HR: 1.11; 95% CI: 1.05-1.17) and a dichotomized variable (high (WBC >= 9) vs. low (WBC <9), (HR: 1.53; 95% CI:1.09-2.15). WBC and absolute neutrophil count (ANC) were highly correlated suggesting that PMNs account for most of this association (r = 0.92). Conclusions: Baseline WBC may impart important and readily available prognostic information in outpatients with IPF. Further studies are warranted to validate this as a potential biomarker for IPF, as well as to define the biologic basis for the association.en_US
dc.description.sponsorshipBoerhinger-Ingelheim; Roche-GenentechRoche HoldingGenentechen_US
dc.description.sponsorshipSDN has received research funding, is on the Speakers' Bureau and has served as a consultant for Boerhinger-Ingelheim and Roche-Genentech. He has also served as a consultant for United Therapeutics, Promedior and Bellerophon. AWB has served on an advisory board for Promedior, Theravance, and Genentech, and serves on the Speakers' Bureau for Genentech.en_US
dc.identifier.doi10.1016/j.rmed.2020.106068en_US
dc.identifier.issn0954-6111
dc.identifier.issn1532-3064
dc.identifier.pmid32843183en_US
dc.identifier.scopus2-s2.0-85087084454en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.rmed.2020.106068
dc.identifier.urihttps://hdl.handle.net/11454/62082
dc.identifier.volume170en_US
dc.identifier.wosWOS:000571749800011en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherW B Saunders Co Ltden_US
dc.relation.ispartofRespiratory Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLung diseasesen_US
dc.subjectInterstitialen_US
dc.subjectIdiopathic pulmonary fibrosisen_US
dc.subjectLeukocyte counten_US
dc.subjectNeutrophilsen_US
dc.subjectBiomarkersen_US
dc.titleThe association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu